Enrico Focaccia

Enrico Focaccia

Auto-generated profile, based on publicly available information

Enrico Focaccia

Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SGSuchira Gallage
Suchira Gallage
JAJose Efren Barragan Avila
Jose Efren Barragan Avila
PRPierluigi Ramadori
Pierluigi Ramadori
EFEnrico Focaccia
Enrico Focaccia
MRMohammad Rahbari
Mohammad Rahbari
MHMathias Heikenwälder
Mathias Heikenwälder

3 December 2017 in Anticancer Research
Verified
Journal Article
Open access
PDF file
ABAlberto Bavelloni
Alberto Bavelloni
GRGiulia Ramazzotti
Giulia Ramazzotti
Alessandro PoliAlessandro Poli
Alessandro Poli
MPManuela Piazzi
Manuela Piazzi
EFEnrico Focaccia
Enrico Focaccia
Irene FaenzaIrene Faenza
Irene Faenza
MicroRNAs (miRNAs) are a group of highly conserved small non-coding RNAs that were found to enhance mRNA degradation or inhibit post-transcriptional translation. Accumulating evidence indicates that miRNAs contribute to tumorigenesis and cancer metastasis. microRNA-210 has been largely studied in the past several years and has been identified as a major miRNA induced under hypoxia. A variety of miR-210 targets have been identified pointing to its role, not only in mitochondrial metabolism, but also in angiogenesis, the DNA damage response, cell proliferation, and apoptosis. Based on earlier research findings, this review aims to provide a current overview on the involvement of miRNA-210 in biological processes and diseases.

8 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KMKatrin Müller
Katrin Müller
HHHanna Honcharova-Biletska
Hanna Honcharova-Biletska
CKChristiane Koppe
Christiane Koppe
MEMichèle Egger
Michèle Egger
LCLap Kwan Chan
Lap Kwan Chan
TLTom Lüdde
Tom Lüdde
The c-Jun N-terminal kinase (JNK) signaling pathway mediates adaptation to stress signals and has been associated with cell death, cell proliferation, and malignant transformation in the liver. However, up to now, its function was experimentally studied mainly in young mice. By generating mice with combined conditional ablation of Jnk1 and Jnk2 in liver parenchymal cells (LPCs) (JNK1/2LPC-KO mice; KO, knockout), we unraveled a function of the JNK pathway in the regulation of liver homeostasis during aging. Aging JNK1/2LPC-KO mice spontaneously developed large biliary cysts that originated from the biliary cell compartment. Mechanistically, we could show that cyst formation in livers of JNK1/2LPC-KO mice was dependent on receptor-interacting protein kinase 1 (RIPK1), a known regulator of cell survival, apoptosis, and necroptosis. In line with this, we showed that RIPK1 was overexpressed in the human cyst epithelium of a subset of patients with polycystic liver disease. Collectively, these data reveal a functional interaction between JNK signaling and RIPK1 in age-related progressive cyst development. Thus, they provide a functional linkage between stress adaptation and programmed cell death (PCD) in the maintenance of liver homeostasis during aging. Significance JNK signaling has been studied intensively in models of liver physiology and disease, but previous studies had focused on young mice. However, it had not been recognized that JNK plays a fundamental role in maintaining liver homeostasis and preventing the formation of biliary cysts in aging mice. These observations call for caution in all long-term pharmacological inhibition strategies targeting the JNK pathway. Finally, our results provide evidence of a molecular link between JNK and the cell-death mediator RIPK1. The specific overexpression of RIPK1 in cysts of a subset of patients with polycystic liver disease suggests that RIPK1 might be mechanistically involved in the pathogenesis of human biliary cysts.

20 July 2017 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
ABAlberto Bavelloni
Alberto Bavelloni
EFEnrico Focaccia
Enrico Focaccia
MPManuela Piazzi
Manuela Piazzi
Costantino ErraniCostantino Errani
Costantino Errani
WBWilliam Blalock
William Blalock
Irene FaenzaIrene Faenza
Irene Faenza
Background/Aim: Kinamycin F is a bacterial metabolite which contains an unusual and potentially reactive diazo group that is known for its ability to inhibit cell growth. In this study, the potential anti-tumor activity of kinamycin F was investigated in three human osteosarcoma cell lines, MG-63, U-2 OS and HOS as an antitumor agent with a potentially novel target. Materials and Methods: Proliferation and cell viability were measured in three human osteosarcoma cell lines by commercially available kits. We also evaluated the effects of the drug on cell cycle progression using the Muse™ Cell Analyzer. Caspase-3 activity was determined by a fluorometric EnzChek assay kit. Finally, following treatment with kinamycin F the protein levels of cyclin D3, cyclin A and cdK-2 were examined. Results: Kinamycin F induced a concentration-dependent cell death in all the three cell lines. Flow cytometry revealed that kinamycin F treatment at 1 μM concentration significantly increased the cell population in the G2/M-phase (60-65%). Kinamycin F activated caspase 3 in all the three cell lines, clearly demonstrating that the growth inhibitory effect of kinamycin F can be attributed to apoptosis induction. Finally, kinamycin F suppressed osteosarcoma cell proliferation affecting cyclin A and D3 expression. Conclusion: Understanding the mechanism by which kinamycin F exerts its ability to inhibit cell growth may be a step forward in the development of new therapeutic strategies for the treatment of OS.

3 April 2017 in RNA & Disease
Verified
Journal Article
Open access
PDF file
WBWilliam Blalock
William Blalock
MPManuela Piazzi
Manuela Piazzi
AGAngela Gallo
Angela Gallo
ABAlberto Bavelloni
Alberto Bavelloni
EFEnrico Focaccia
Enrico Focaccia
IFIrene Faenza
Irene Faenza
Bone marrow failure disorders (BMFDs), which are characterized by an early pro-apoptotic phase which results in faulty hematopoiesis and anemia, more often than not progress to outright acute myelogenous leukemia (AML). Recent findings have indicated that most if not all of these disorders have a very significant RNA processing component to their pathology. This review aims to highlight some of normal processes of RNA metabolism that have been recently demonstrated to be altered in BMFDs.